Ontology highlight
ABSTRACT:
SUBMITTER: Catalanotti F
PROVIDER: S-EPMC3932005 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature
Catalanotti Federica F Solit David B DB Pulitzer Melissa P MP Berger Michael F MF Scott Sasinya N SN Iyriboz Tunc T Lacouture Mario E ME Panageas Katherine S KS Wolchok Jedd D JD Carvajal Richard D RD Schwartz Gary K GK Rosen Neal N Chapman Paul B PB
Clinical cancer research : an official journal of the American Association for Cancer Research 20130226 8
<h4>Purpose</h4>Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated.<h4>Experimental design</h4>We conducted a phase II trial in patients with melanoma whose tumors harbored a BRAF mutation. Patients were stratified by phosphorylated-AKT (pAKT) expression (high vs. low) and treated with selumetinib 75 mg per os twice daily. Pretreatment tumors were also analyzed for gen ...[more]